Skip to main content
NCBI home page
The Journal of Cell Biology logoLink to The Journal of Cell Biology
. 1987 Apr 1;104(4):1085–1096. doi: 10.1083/jcb.104.4.1085

Distinct localizations of urokinase-type plasminogen activator and its type 1 inhibitor under cultured human fibroblasts and sarcoma cells

PMCID: PMC2114427  PMID: 3104349

Abstract

We studied the immunocytochemical localization of urokinase-type plasminogen activator (u-PA) and the type 1 plasminogen activator inhibitor (PAI-1) in human fibroblasts and sarcoma cells, using both polyclonal and monoclonal antibodies. The u-PA was found to be located at discrete cell-substratum contact sites, and also at areas of cell- cell contacts, whereas PAI-1 was distributed as a homogeneous carpet excluding strialike areas on the substrate under the cells. To confirm the extracellular localization of u-PA and PAI-1, we stained the cells live at 0 degree C before fixation. A double-labeling experiment showed different distribution of u-PA and PAI-1 under the cells, and especially their peripheral parts. The staining pattern of u-PA and PAI- 1 resisted treatment with 0.2% saponin followed by mechanical removal of cells, a method previously reported to isolate focal contact membranes of fibroblasts. We further demonstrated the deposition of u- PA to the contact areas of cells obtained by saponin treatment by zymography, and that of PAI-1 by metabolic labeling, reverse zymography, immunoblotting, and immunoprecipitation. Fibronectin was also present in the preparations. The deposition of both PAI-1 and fibronectin by the sarcoma cells was enhanced, after treating the cells with 10(-6) M dexamethasone. The confinement of u-PA to discrete contact sites and the more uniform distribution of PAI-1 on the cell substratum may explain how cells producing large amounts of enzyme inhibitors can produce PA-mediated focal proteolysis.

Full Text

The Full Text of this article is available as a PDF (5.0 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alitalo K., Kurkinen M., Vaheri A., Virtanen I., Rohde H., Timpl R. Basal lamina glycoproteins are produced by neuroblastoma cells. Nature. 1980 Oct 2;287(5781):465–466. doi: 10.1038/287465a0. [DOI] [PubMed] [Google Scholar]
  2. Andreasen P. A., Christensen T. H., Huang J. Y., Nielsen L. S., Wilson E. L., Danø K. Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Mol Cell Endocrinol. 1986 May;45(2-3):137–147. doi: 10.1016/0303-7207(86)90141-3. [DOI] [PubMed] [Google Scholar]
  3. Andreasen P. A., Nielsen L. S., Grøndahl-Hansen J., Skriver L., Zeuthen J., Stephens R. W., Danø K. Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody. EMBO J. 1984 Jan;3(1):51–56. doi: 10.1002/j.1460-2075.1984.tb01760.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Andreasen P. A., Nielsen L. S., Kristensen P., Grøndahl-Hansen J., Skriver L., Danø K. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme. J Biol Chem. 1986 Jun 15;261(17):7644–7651. [PubMed] [Google Scholar]
  5. Astedt B., Lecander I., Brodin T., Lundblad A., Löw K. Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost. 1985 Feb 18;53(1):122–125. [PubMed] [Google Scholar]
  6. Avnur Z., Geiger B. Substrate-attached membranes of cultured cells isolation and characterization of ventral cell membranes and the associated cytoskeleton. J Mol Biol. 1981 Dec 5;153(2):361–379. doi: 10.1016/0022-2836(81)90283-7. [DOI] [PubMed] [Google Scholar]
  7. Barnes D. W., Silnutzer J., See C., Shaffer M. Characterization of human serum spreading factor with monoclonal antibody. Proc Natl Acad Sci U S A. 1983 Mar;80(5):1362–1366. doi: 10.1073/pnas.80.5.1362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bayley S. A., Rees D. A. Analysis of the proteins, glycoproteins and glycosaminoglycans of fibroblast adhesions to substratum. Biochim Biophys Acta. 1982 Jul 28;689(2):351–362. doi: 10.1016/0005-2736(82)90269-3. [DOI] [PubMed] [Google Scholar]
  9. Bloch R. J. Isolation of acetylcholine receptor clusters in substrate-associated material from cultured rat myotubes using saponin. J Cell Biol. 1984 Sep;99(3):984–993. doi: 10.1083/jcb.99.3.984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Carter W. G., Hakomori S. A new cell surface, detergent-insoluble glycoprotein matrix of human and hamster fibroblasts. The role of disulfide bonds in stabilization of the matrix. J Biol Chem. 1981 Jul 10;256(13):6953–6960. [PubMed] [Google Scholar]
  11. Chapman H. A., Jr, Vavrin Z., Hibbs J. B., Jr Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell. 1982 Mar;28(3):653–662. doi: 10.1016/0092-8674(82)90220-3. [DOI] [PubMed] [Google Scholar]
  12. Chen W. T., Olden K., Bernard B. A., Chu F. F. Expression of transformation-associated protease(s) that degrade fibronectin at cell contact sites. J Cell Biol. 1984 Apr;98(4):1546–1555. doi: 10.1083/jcb.98.4.1546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  14. Crutchley D. J., Conanan L. B., Maynard J. R. Human fibroblasts produce inhibitor directed against plasminogen activator when treated with glucocorticoids. Ann N Y Acad Sci. 1981;370:609–616. doi: 10.1111/j.1749-6632.1981.tb29767.x. [DOI] [PubMed] [Google Scholar]
  15. Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
  16. Eaton D. L., Scott R. W., Baker J. B. Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. J Biol Chem. 1984 May 25;259(10):6241–6247. [PubMed] [Google Scholar]
  17. Emeis J. J., van Hinsbergh V. W., Verheijen J. H., Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Commun. 1983 Jan 27;110(2):392–398. doi: 10.1016/0006-291x(83)91161-0. [DOI] [PubMed] [Google Scholar]
  18. Erickson L. A., Ginsberg M. H., Loskutoff D. J. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest. 1984 Oct;74(4):1465–1472. doi: 10.1172/JCI111559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Erickson L. A., Lawrence D. A., Loskutoff D. J. Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem. 1984 Mar;137(2):454–463. doi: 10.1016/0003-2697(84)90113-1. [DOI] [PubMed] [Google Scholar]
  20. Fibbi G., Dini G., Pasquali F., Pucci M., Del Rosso M. The Mr 17500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells. Biochim Biophys Acta. 1986 Mar 14;885(3):301–308. doi: 10.1016/0167-4889(86)90245-4. [DOI] [PubMed] [Google Scholar]
  21. Golder J. P., Stephens R. W. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem. 1983 Nov 15;136(3):517–522. doi: 10.1111/j.1432-1033.1983.tb07771.x. [DOI] [PubMed] [Google Scholar]
  22. Granelli-Piperno A., Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978 Jul 1;148(1):223–234. doi: 10.1084/jem.148.1.223. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Hayman E. G., Pierschbacher M. D., Ohgren Y., Ruoslahti E. Serum spreading factor (vitronectin) is present at the cell surface and in tissues. Proc Natl Acad Sci U S A. 1983 Jul;80(13):4003–4007. doi: 10.1073/pnas.80.13.4003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Hedman K., Vaheri A., Wartiovaara J. External fibronectin of cultured human fibroblasts is predominantly a matrix protein. J Cell Biol. 1978 Mar;76(3):748–760. doi: 10.1083/jcb.76.3.748. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Holmberg L., Lecander I., Persson B., Astedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta. 1978 Nov 15;544(1):128–137. doi: 10.1016/0304-4165(78)90216-7. [DOI] [PubMed] [Google Scholar]
  26. Ichinose A., Kisiel W., Fujikawa K. Proteolytic activation of tissue plasminogen activator by plasma and tissue enzymes. FEBS Lett. 1984 Oct 1;175(2):412–418. doi: 10.1016/0014-5793(84)80779-6. [DOI] [PubMed] [Google Scholar]
  27. Jaken S., Black P. H. Correlation between a specific molecular weight form of plasminogen activator and metabolic activity of 3T3 cells. J Cell Biol. 1981 Sep;90(3):721–726. doi: 10.1083/jcb.90.3.721. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Jaken S., Black P. H. Differences in intracellular distribution of plasminogen activator in growing, confluent, and transformed 3T3 cells. Proc Natl Acad Sci U S A. 1979 Jan;76(1):246–250. doi: 10.1073/pnas.76.1.246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Kawano T., Morimoto K., Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem. 1970 Mar;67(3):333–342. doi: 10.1093/oxfordjournals.jbchem.a129257. [DOI] [PubMed] [Google Scholar]
  30. Keski-Oja J., Vaheri A. The cellular target for the plasminogen activator, urokinase, in human fibroblasts - 66 000 dalton protein. Biochim Biophys Acta. 1982 Apr 29;720(2):141–146. doi: 10.1016/0167-4889(82)90005-2. [DOI] [PubMed] [Google Scholar]
  31. Kielberg V., Andreasen P. A., Grøndahl-Hansen J., Nielsen L. S., Skriver L., Danø K. Proenzyme to urokinase-type plasminogen activator in the mouse in vivo. FEBS Lett. 1985 Mar 25;182(2):441–445. doi: 10.1016/0014-5793(85)80350-1. [DOI] [PubMed] [Google Scholar]
  32. Kristensen P., Larsson L. I., Nielsen L. S., Grøndahl-Hansen J., Andreasen P. A., Danø K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984 Mar 12;168(1):33–37. doi: 10.1016/0014-5793(84)80201-x. [DOI] [PubMed] [Google Scholar]
  33. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  34. Lark M. W., Laterra J., Culp L. A. Close and focal contact adhesions of fibroblasts to a fibronectin-containing matrix. Fed Proc. 1985 Feb;44(2):394–403. [PubMed] [Google Scholar]
  35. Larsson L. I., Skriver L., Nielsen L. S., Grøndahl-Hansen J., Kristensen P., Danø K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol. 1984 Mar;98(3):894–903. doi: 10.1083/jcb.98.3.894. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Laug W. E., Dewald B., Schnyder J., Baggiolini M. Subcellular distribution of plasminogen activator in cultured human fibrosarcoma cells. Cancer Res. 1983 Jan;43(1):22–27. [PubMed] [Google Scholar]
  37. Lehto V. P., Vartio T., Virtanen I. Enrichment of a 140 KD surface glycoprotein in adherent, detergent-resistant cytoskeletons of cultured human fibroblasts. Biochem Biophys Res Commun. 1980 Aug 14;95(3):909–916. doi: 10.1016/0006-291x(80)91559-4. [DOI] [PubMed] [Google Scholar]
  38. Lemaire G., Drapier J. C., Petit J. F. Importance, localization and functional properties of the cell-associated form of plasminogen activator in mouse peritoneal macrophages. Biochim Biophys Acta. 1983 Feb 22;755(3):332–343. doi: 10.1016/0304-4165(83)90235-0. [DOI] [PubMed] [Google Scholar]
  39. Levin E. G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804–6808. doi: 10.1073/pnas.80.22.6804. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Loskutoff D. J., Edgington T. E. Synthesis of a fibrinolytic activator and inhibitor by endothelial cells. Proc Natl Acad Sci U S A. 1977 Sep;74(9):3903–3907. doi: 10.1073/pnas.74.9.3903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Loskutoff D. J., Edgington T. S. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem. 1981 May 10;256(9):4142–4145. [PubMed] [Google Scholar]
  42. Lucas M. A., Fretto L. J., McKee P. A. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem. 1983 Apr 10;258(7):4249–4256. [PubMed] [Google Scholar]
  43. Mullins D. E., Rohrlich S. T. The role of proteinases in cellular invasiveness. Biochim Biophys Acta. 1983 Dec 29;695(3-4):177–214. doi: 10.1016/0304-419x(83)90011-2. [DOI] [PubMed] [Google Scholar]
  44. Neyfakh A. A., Jr, Svitkina T. M. Isolation of focal contact membrane using saponin. Exp Cell Res. 1983 Dec;149(2):582–586. doi: 10.1016/0014-4827(83)90369-5. [DOI] [PubMed] [Google Scholar]
  45. Neyfakh A. A., Jr, Tint I. S., Svitkina T. M., Bershadsky A. D., Gelfand V. I. Visualization of cellular focal contacts using a monoclonal antibody to 80 kD serum protein adsorbed on the substratum. Exp Cell Res. 1983 Dec;149(2):387–396. doi: 10.1016/0014-4827(83)90351-8. [DOI] [PubMed] [Google Scholar]
  46. Nielsen L. S., Andreasen P. A., Grøndahl-Hansen J., Huang J. Y., Kristensen P., Danø K. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Thromb Haemost. 1986 Apr 30;55(2):206–212. [PubMed] [Google Scholar]
  47. Nielsen L. S., Hansen J. G., Andreasen P. A., Skriver L., Danø K., Zeuthen J. Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification. EMBO J. 1983;2(1):115–119. doi: 10.1002/j.1460-2075.1983.tb01391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Nielsen L. S., Hansen J. G., Skriver L., Wilson E. L., Kaltoft K., Zeuthen J., Danø K. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. Biochemistry. 1982 Dec 7;21(25):6410–6415. doi: 10.1021/bi00268a014. [DOI] [PubMed] [Google Scholar]
  49. O'Grady R. L., Upfold L. I., Stephens R. W. Rat mammary carcinoma cells secrete active collagenase and activate latent enzyme in the stroma via plasminogen activator. Int J Cancer. 1981 Oct 15;28(4):509–515. doi: 10.1002/ijc.2910280418. [DOI] [PubMed] [Google Scholar]
  50. Oliver N., Newby R. F., Furcht L. T., Bourgeois S. Regulation of fibronectin biosynthesis by glucocorticoids in human fibrosarcoma cells and normal fibroblasts. Cell. 1983 May;33(1):287–296. doi: 10.1016/0092-8674(83)90357-4. [DOI] [PubMed] [Google Scholar]
  51. Paranjpe M., Engel L., Young N., Liotta L. A. Activation of human breast carcinoma collagenase through plasminogen activator. Life Sci. 1980 Apr 14;26(15):1223–1231. doi: 10.1016/0024-3205(80)90067-3. [DOI] [PubMed] [Google Scholar]
  52. Paul D. C., Bobbitt J. L., Williams D. C., Hull R. N. Immunocytochemical localization of plasminogen activator on porcine kidney cell strain: LLC-PK1 (LP100). J Histochem Cytochem. 1979 Jun;27(6):1035–1040. doi: 10.1177/27.6.88472. [DOI] [PubMed] [Google Scholar]
  53. Philips M., Juul A. G., Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta. 1984 Nov 6;802(1):99–110. doi: 10.1016/0304-4165(84)90039-4. [DOI] [PubMed] [Google Scholar]
  54. Quigley J. P. Association of a protease (plasminogen activator) with a specific membrane fraction isolated from transformed cells. J Cell Biol. 1976 Nov;71(2):472–486. doi: 10.1083/jcb.71.2.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta. 1985 Nov 12;823(1):35–65. doi: 10.1016/0304-419x(85)90014-9. [DOI] [PubMed] [Google Scholar]
  56. Salo T., Liotta L. A., Keski-Oja J., Turpeenniemi-Hujanen T., Tryggvason K. Secretion of basement membrane collagen degrading enzyme and plasminogen activator by transformed cells--role in metastasis. Int J Cancer. 1982 Nov 15;30(5):669–673. doi: 10.1002/ijc.2910300520. [DOI] [PubMed] [Google Scholar]
  57. Salonen E. M., Saksela O., Vartio T., Vaheri A., Nielsen L. S., Zeuthen J. Plasminogen and tissue-type plasminogen activator bind to immobilized fibronectin. J Biol Chem. 1985 Oct 5;260(22):12302–12307. [PubMed] [Google Scholar]
  58. Salonen E. M., Zitting A., Vaheri A. Laminin interacts with plasminogen and its tissue-type activator. FEBS Lett. 1984 Jun 25;172(1):29–32. doi: 10.1016/0014-5793(84)80866-2. [DOI] [PubMed] [Google Scholar]
  59. Scott R. W., Baker J. B. Purification of human protease nexin. J Biol Chem. 1983 Sep 10;258(17):10439–10444. [PubMed] [Google Scholar]
  60. Scott R. W., Bergman B. L., Bajpai A., Hersh R. T., Rodriguez H., Jones B. N., Barreda C., Watts S., Baker J. B. Protease nexin. Properties and a modified purification procedure. J Biol Chem. 1985 Jun 10;260(11):7029–7034. [PubMed] [Google Scholar]
  61. Seifert S. C., Gelehrter T. D. Mechanism of dexamethasone inhibition of plasminogen activator in rat hepatoma cells. Proc Natl Acad Sci U S A. 1978 Dec;75(12):6130–6133. doi: 10.1073/pnas.75.12.6130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Shulman M., Wilde C. D., Köhler G. A better cell line for making hybridomas secreting specific antibodies. Nature. 1978 Nov 16;276(5685):269–270. doi: 10.1038/276269a0. [DOI] [PubMed] [Google Scholar]
  63. Skriver L., Larsson L. I., Kielberg V., Nielsen L. S., Andresen P. B., Kristensen P., Danø K. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol. 1984 Aug;99(2):753–757. doi: 10.1083/jcb.99.2.753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Skriver L., Nielsen L. S., Stephens R., Danø K. Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. Eur J Biochem. 1982 May 17;124(2):409–414. doi: 10.1111/j.1432-1033.1982.tb06608.x. [DOI] [PubMed] [Google Scholar]
  65. Solomon J. A., Chou I. N., Schroder E. W., Black P. H. Evidence for membrane association of plasminogen activator activity in mouse macrophages. Biochem Biophys Res Commun. 1980 May 30;94(2):480–486. doi: 10.1016/0006-291x(80)91256-5. [DOI] [PubMed] [Google Scholar]
  66. Sprengers E. D., Verheijen J. H., Van Hinsbergh V. W., Emeis J. J. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta. 1984 Sep 28;801(2):163–170. doi: 10.1016/0304-4165(84)90063-1. [DOI] [PubMed] [Google Scholar]
  67. Stoppelli M. P., Corti A., Soffientini A., Cassani G., Blasi F., Assoian R. K. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci U S A. 1985 Aug;82(15):4939–4943. doi: 10.1073/pnas.82.15.4939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979 Sep;76(9):4350–4354. doi: 10.1073/pnas.76.9.4350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Vartio T., Barlati S., de Petro G., Miggiano V., Stähli C., Takács B., Vaheri A. Evidence for preferential proteolytic cleavage of one of the two fibronectin subunits and for immunological localization of a site distinguishing them. Eur J Biochem. 1983 Sep 15;135(2):203–207. doi: 10.1111/j.1432-1033.1983.tb07638.x. [DOI] [PubMed] [Google Scholar]
  70. Vartio T., Salonen E. M., De Petro G., Barlati S., Miggiano V., Stähli C., Virgallita G., Takács B., Vaheri A. Monoclonal antibody against the N-terminal end of human plasma fibronectin. Biochem J. 1983 Oct 1;215(1):147–151. doi: 10.1042/bj2150147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Vartio T., Seppä H., Vaheri A. Susceptibility of soluble and matrix fibronectins to degradation by tissue proteinases, mast cell chymase and cathepsin G. J Biol Chem. 1981 Jan 10;256(1):471–477. [PubMed] [Google Scholar]
  72. Vartio T., Zardi L., Balza E., Towbin H., Vaheri A. Monoclonal antibodies in analysis of cathepsin G-digested proteolytic fragments of human plasma fibronectin. J Immunol Methods. 1982 Dec 30;55(3):309–318. doi: 10.1016/0022-1759(82)90090-4. [DOI] [PubMed] [Google Scholar]
  73. Vassalli J. D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985 Jan;100(1):86–92. doi: 10.1083/jcb.100.1.86. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Vassalli J. D., Dayer J. M., Wohlwend A., Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med. 1984 Jun 1;159(6):1653–1668. doi: 10.1084/jem.159.6.1653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Verheijen J. H., Chang G. T., Kluft C. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma. Thromb Haemost. 1984 Jul 29;51(3):392–395. [PubMed] [Google Scholar]
  76. Wiman B., Chmielewska J., Rånby M. Inactivation of tissue plasminogen activator in plasma. Demonstration of a complex with a new rapid inhibitor. J Biol Chem. 1984 Mar 25;259(6):3644–3647. [PubMed] [Google Scholar]
  77. Wun T. C., Ossowski L., Reich E. A proenzyme form of human urokinase. J Biol Chem. 1982 Jun 25;257(12):7262–7268. [PubMed] [Google Scholar]
  78. van Mourik J. A., Lawrence D. A., Loskutoff D. J. Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells. J Biol Chem. 1984 Dec 10;259(23):14914–14921. [PubMed] [Google Scholar]

Articles from The Journal of Cell Biology are provided here courtesy of The Rockefeller University Press

RESOURCES